Gemcitabine

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW):263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00

カスタマーフィードバック(4)

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M1;qUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXIZmZFUUN3ME2wMlAxODR3ODDuUS=> MV;TRW5ITVJ?
ES4 NXvxeXFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DsUGlEPTB;MD6wNFA3PTNibl2= M2jBR3NCVkeHUh?=
ACHN NG\5TYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HtcGlEPTB;MD6wNFA5QDdibl2= NFjtUm5USU6JRWK=
KYSE-510 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMECwPVc2KG6P M3;BbXNCVkeHUh?=
EW-7 NXfkeFMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfmTWM2OD1yLkCwNlU5KG6P NEPQNHlUSU6JRWK=
BFTC-905 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XPTGlEPTB;MD6wNFUyPSCwTR?= M2[2cHNCVkeHUh?=
KE-37 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfnTWM2OD1yLkCwOVYyKG6P M3PqR3NCVkeHUh?=
SBC-5 NH:5eYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjITWM2OD1yLkCwOVchdk1? M3LZXnNCVkeHUh?=
NKM-1 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Lb41KSzVyPUCuNFA4ODlibl2= M3\I[XNCVkeHUh?=
RH-1 NV;RZ3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHDcVd6UUN3ME2wMlAxPzF6IH7N NU\nOWdTW0GQR1XS
ALL-PO MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEC4N{BvVQ>? MUDTRW5ITVJ?
QIMR-WIL M2fnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEC4PVQhdk1? NV:1eItIW0GQR1XS
A375 NXjVUHpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMEC5PVUhdk1? NHi4PGZUSU6JRWK=
SIG-M5 M3fyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzSTWM2OD1yLkCxNFQhdk1? MVXTRW5ITVJ?
KGN NXnJ[2NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjzUGlKSzVyPUCuNFExQCCwTR?= NHHMXVVUSU6JRWK=
EW-13 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmxb4x{UUN3ME2wMlAyOTJibl2= NEe0W2hUSU6JRWK=
NCI-SNU-1 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rvZWlEPTB;MD6wNVYhdk1? NHfzZ3ZUSU6JRWK=
PSN1 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEG2OUBvVQ>? MmLGV2FPT0WU
HUTU-80 NFLKT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXZTWM2OD1yLkCxOlYhdk1? NGXWbVhUSU6JRWK=
EW-16 NFWySFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXflU5JiUUN3ME2wMlAzOyCwTR?= NGT0PYpUSU6JRWK=
786-0 NGLpcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPxTWM2OD1yLkCyN{BvVQ>? MmqxV2FPT0WU
ES1 NELudI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEK2PEBvVQ>? MX;TRW5ITVJ?
RKO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEK3PUBvVQ>? MW\TRW5ITVJ?
ESS-1 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\sOmlEPTB;MD6wNlg3KG6P NYXuWFZDW0GQR1XS
SK-UT-1 M3rsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\SVmlEPTB;MD6wNlk4KG6P M{DpSnNCVkeHUh?=
LB2241-RCC MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzJdZZKSzVyPUCuNFMyQCCwTR?= MkLsV2FPT0WU
CHL-1 M3;wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEOyOEBvVQ>? NHHVb4NUSU6JRWK=
SW1783 NHH5UYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMEOzOkBvVQ>? MVLTRW5ITVJ?
MEL-JUSO NYmyRnUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjnfm5[UUN3ME2wMlA{QTFibl2= NEXDR|BUSU6JRWK=
HT-29 NUe0XVQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW3eWZKSzVyPUCuNFQyOyCwTR?= MYPTRW5ITVJ?
SNG-M NHHBfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjNWnRKSzVyPUCuNFQzPSCwTR?= NEDINlNUSU6JRWK=
TE-15 M13HWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqyWGdKSzVyPUCuNFQ3PCCwTR?= NV:3SGRkW0GQR1XS
HOS NETweJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDaRYxwUUN3ME2wMlA1QCCwTR?= Ml;kV2FPT0WU
BB65-RCC NGfTWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThTHBDUUN3ME2wMlA2OTJibl2= M2LCXnNCVkeHUh?=
HCE-4 NIXJSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPUTWM2OD1yLkC1Nlghdk1? MnniV2FPT0WU
MHH-ES-1 M3HsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmmwTWM2OD1yLkC1N|Ehdk1? M1LkSHNCVkeHUh?=
RPMI-7951 M1HSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD2Z5dHUUN3ME2wMlA2PDFibl2= M1rWWnNCVkeHUh?=
IST-SL2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfWdnFKSzVyPUCuNFU5PCCwTR?= MlLmV2FPT0WU
CMK Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEW4OkBvVQ>? M{TY[3NCVkeHUh?=
GR-ST M{H4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfVOldyUUN3ME2wMlA2QTVibl2= M{\VSnNCVkeHUh?=
NALM-6 NF7jOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:0NWVJUUN3ME2wMlA3OjJibl2= MVnTRW5ITVJ?
RPMI-6666 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jUeWlEPTB;MD6wOlUzKG6P Ml;tV2FPT0WU
LC-2-ad MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;3VXN5UUN3ME2wMlA3PTNibl2= NWPQfXp2W0GQR1XS
ARH-77 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHTTWM2OD1yLkC3NVEhdk1? NHi5XYxUSU6JRWK=
IST-MEL1 NUXKb3lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMEeyOkBvVQ>? M2TYc3NCVkeHUh?=
SW1710 M3Xs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfSTWM2OD1yLkC3OVEhdk1? NYC5XZZHW0GQR1XS
DEL NEDhVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTBUIJKSzVyPUCuNFg5PyCwTR?= MXvTRW5ITVJ?
AGS M2jVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DDdWlEPTB;MD6wPVAzKG6P MYjTRW5ITVJ?
NCI-H2122 NVzDWnlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4eyNmlEPTB;MD6wPVQ3KG6P NV22Xm1XW0GQR1XS
HSC-4 NFrzPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMUCyJI5O MX3TRW5ITVJ?
AM-38 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHpR|JoUUN3ME2wMlEzOSCwTR?= NWTWU2kxW0GQR1XS
769-P M13yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jiRmlEPTB;MD6xNlMhdk1? MkD6V2FPT0WU
RT-112 NFnrcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[3cpljUUN3ME2wMlEzPyCwTR?= NUWxOnlVW0GQR1XS
MCF7 M1nFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMUO2JI5O MYPTRW5ITVJ?
IGROV-1 M37UcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXrZ3FRUUN3ME2wMlE1PSCwTR?= NH;Ec2RUSU6JRWK=
OCI-AML2 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H3bmlEPTB;MD6xOFchdk1? MnT0V2FPT0WU
NCI-H1299 M{LBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHZ[|BEUUN3ME2wMlE2PyCwTR?= M4n1UHNCVkeHUh?=
A431 NFzXZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfKTWM2OD1yLkG4N{BvVQ>? NG\jeWJUSU6JRWK=
SW982 M1nUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH4TWM2OD1yLkKxN{BvVQ>? NVX4V5d1W0GQR1XS
BB30-HNC NEWxeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMkOxJI5O NUXNSYFjW0GQR1XS
ACN NIW1SlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPuN|gyUUN3ME2wMlI1PCCwTR?= M3fs[3NCVkeHUh?=
647-V NFvPfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGezZ4JKSzVyPUCuNlQ5KG6P NGHxS5FUSU6JRWK=
SK-PN-DW MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMk[2JI5O M4ThR3NCVkeHUh?=
LCLC-97TM1 NUX0RpVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXrTWM2OD1yLkK2O{BvVQ>? NELjN4ZUSU6JRWK=
LB1047-RCC Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPMTWM2OD1yLkK2PUBvVQ>? NV;0XZpNW0GQR1XS
A2780 M37TTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES1fI1KSzVyPUCuNlchdk1? MojoV2FPT0WU
C-33-A MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMkezJI5O M2XvSHNCVkeHUh?=
NCI-H2228 NEGxPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3lUYVPUUN3ME2wMlMyPCCwTR?= MlnkV2FPT0WU
TE-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrCOVNKSzVyPUCuN|E3KG6P NFO3T|NUSU6JRWK=
HC-1 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwM{K3JI5O M{L5THNCVkeHUh?=
SK-MES-1 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvIeVNWUUN3ME2wMlMzQCCwTR?= NXvR[45LW0GQR1XS
NCI-H1355 MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HxZ2lEPTB;MD6zPFEhdk1? M3\LdHNCVkeHUh?=
YKG-1 NX\sNFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwNEG5JI5O MkLkV2FPT0WU
RS4-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvtclJXUUN3ME2wMlQ{OyCwTR?= MnGyV2FPT0WU
Daoy M4rRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrIW4p5UUN3ME2wMlQ2PiCwTR?= MVHTRW5ITVJ?
A3-KAW M{jUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzITWM2OD1yLkW1NUBvVQ>? MnfxV2FPT0WU
SK-MEL-30 M1TMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwNUW0JI5O MV;TRW5ITVJ?
U031 NUHCfoxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrvcnV7UUN3ME2wMlU3PSCwTR?= NHHacGhUSU6JRWK=
SK-LMS-1 M1PEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojUTWM2OD1yLkW3PEBvVQ>? M4XEOXNCVkeHUh?=
ES6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S2RmlEPTB;MD61PFYhdk1? NX3FSYl1W0GQR1XS
EoL-1-cell MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrWU|ZKSzVyPUCuOlE3KG6P MlLrV2FPT0WU
NCI-H2009 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HPbGlEPTB;MD62NVkhdk1? NVH5TnBsW0GQR1XS
A4-Fuk MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPxcolKSzVyPUCuOlI3KG6P NIfsVWNUSU6JRWK=
KYSE-270 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwNkO0JI5O MnjYV2FPT0WU
SK-LU-1 NEX0O4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz4RmJKSzVyPUCuOlU2KG6P NIXocVZUSU6JRWK=
SW872 NFS4UlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm4OnhKSzVyPUCuO|Y2KG6P MkPPV2FPT0WU
ES8 M1vpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ezXmlEPTB;MD63PEBvVQ>? MmXRV2FPT0WU
G-402 NHPh[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonMTWM2OD1yLke4OEBvVQ>? MlfDV2FPT0WU
ATN-1 M{iyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPJTWM2OD1yLkiwO{BvVQ>? MlrUV2FPT0WU
DoTc2-4510 NV\VNJBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vzO2lEPTB;MD65NFEhdk1? MlLpV2FPT0WU
MES-SA MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX0TWM2OD1yLkmwOUBvVQ>? NGflT5RUSU6JRWK=
SF268 NGDmOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwOUK3JI5O MmHUV2FPT0WU
SF539 NVL5RoFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwMEKgcm0> NWjKSZJLW0GQR1XS
NB69 M4DP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W0RWlEPTB;MT6wOUBvVQ>? M{\lOHNCVkeHUh?=
8505C MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHBTWM2OD1zLkC2JI5O M1XKOHNCVkeHUh?=
CAL-12T M3Pz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3DbXFwUUN3ME2xMlA5KG6P NFXCN4JUSU6JRWK=
BHY NV7LTHV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwMUSgcm0> MVjTRW5ITVJ?
LB647-SCLC NV7PXGlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj6XZFkUUN3ME2xMlE5KG6P MXPTRW5ITVJ?
CAL-62 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;DWWlEPTB;MT6yNkBvVQ>? Mo\3V2FPT0WU
MEG-01 M3LRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK0SYpXUUN3ME2xMlI4KG6P MlrxV2FPT0WU
MG-63 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nvdGlEPTB;MT6zN{BvVQ>? NHvpOZhUSU6JRWK=
SW620 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PCVWlEPTB;MT6zOUBvVQ>? MVvTRW5ITVJ?
A388 NW[5VpdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILpVpJKSzVyPUGuN|Yhdk1? NGnOZY5USU6JRWK=
BCPAP Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXWb3B[UUN3ME2xMlQ2KG6P M3eyXnNCVkeHUh?=
P30-OHK M2\semdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwNE[gcm0> M2W0S3NCVkeHUh?=
Ca9-22 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSzfJdKSzVyPUGuOVQhdk1? M2P0SnNCVkeHUh?=
VMRC-RCZ Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7DTWM2OD1zLkW0JI5O NYfNenVrW0GQR1XS
LOXIMVI MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:3RVRKSzVyPUGuOkBvVQ>? M1fnTnNCVkeHUh?=
L-540 NWD2Zm5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPtVpdKSzVyPUGuOkBvVQ>? NX3Gb3IzW0GQR1XS
NTERA-S-cl-D1 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrXTWM2OD1zLk[0JI5O NHG4SZJUSU6JRWK=
MFH-ino MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr3OndKSzVyPUGuOlYhdk1? MWLTRW5ITVJ?
Calu-6 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwN{Ogcm0> MmjLV2FPT0WU
HEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS5fHFjUUN3ME2xMlc6KG6P MXrTRW5ITVJ?
CAL-33 M3HFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPTTWM2OD1zLki5JI5O MXXTRW5ITVJ?
HSC-3 NVXsSWRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwOUGgcm0> M4rUeXNCVkeHUh?=
KU812 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjH[XNKSzVyPUGuPVEhdk1? NFHJRYxUSU6JRWK=
EB2 NH:1UmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf0cXhKSzVyPUKuNFEhdk1? NYXvZ|F2W0GQR1XS
SR M37PWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwMUKgcm0> Mne5V2FPT0WU
NCI-H2087 MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\ZVnl4UUN3ME2yMlE1KG6P NELCWYZUSU6JRWK=
H4 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i4eGlEPTB;Mj6xPEBvVQ>? NUL1d3Z7W0GQR1XS
EW-1 NFvBfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXWcY9KSzVyPUKuNlIhdk1? MnrmV2FPT0WU
MC-IXC M1z2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwMk[gcm0> MUXTRW5ITVJ?
NCI-H727 NIm5cGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\nUmlEPTB;Mj61NUBvVQ>? NYfYdWY6W0GQR1XS
MRK-nu-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[0TWM2OD1{LkW3JI5O NUG1NGdGW0GQR1XS
COLO-668 NV;tfm53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWzTWM2OD1{Lk[2JI5O M1vBSnNCVkeHUh?=
CGTH-W-1 M{j2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\QTWM2OD1{LkeyJI5O NXWxU4llW0GQR1XS
CHP-212 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwN{Wgcm0> MYHTRW5ITVJ?
GI-1 NXHrPHJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTlXXliUUN3ME2yMlc3KG6P M{TacXNCVkeHUh?=
HCC1806 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3yWIVCUUN3ME2yMlkyKG6P NX[2cIdtW0GQR1XS
HLE NX6yR|hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LyS2lEPTB;MzDuUS=> M13zfXNCVkeHUh?=
HSC-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3iwdmlEPTB;Mz6wN{BvVQ>? MnXIV2FPT0WU
DMS-273 M2O1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\uSXNsUUN3ME2zMlA4KG6P NVK1R5pVW0GQR1XS
DU-4475 NXXYO3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i1VmlEPTB;Mz6xOEBvVQ>? MWfTRW5ITVJ?
LXF-289 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XQeWlEPTB;Mz6zNUBvVQ>? NFjRS|dUSU6JRWK=
PANC-03-27 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjWN5RKSzVyPUOuOVEhdk1? NIfETYtUSU6JRWK=
GAMG NHf6VldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7JTWM2OD1|Lke0JI5O NXTycVVvW0GQR1XS
NCI-H522 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TqPGlEPTB;ND6zOEBvVQ>? MX;TRW5ITVJ?
SW626 NIfTTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3qTWM2OD12LkS2JI5O NEjHW41USU6JRWK=
HT-144 M3\kWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIToSY9KSzVyPUSuPVIhdk1? M1TX[nNCVkeHUh?=
MEL-HO NXn2[I5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ObI5vUUN3ME21MlE3KG6P NFjwem5USU6JRWK=
BE-13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPJTWM2OD13LkKxJI5O NUL3W2YyW0GQR1XS
VA-ES-BJ NH74W|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrZPVJKSzVyPUWuNlYhdk1? MXTTRW5ITVJ?
NCI-H441 NXTTNYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrGW2lKSzVyPUWuOkBvVQ>? M2\LRXNCVkeHUh?=
KP-4 NVu3SVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTVwNkGgcm0> NYHpdYlSW0GQR1XS
LoVo NYjqcXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTVwN{Ggcm0> NYrMR|ZPW0GQR1XS
HT-1080 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PvU2lEPTB;NT64N{BvVQ>? NWruRmhzW0GQR1XS
GB-1 NITIcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTVwOESgcm0> NEHTZZdUSU6JRWK=
IA-LM NG\UNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXrTWM2OD13LkmxJI5O MYfTRW5ITVJ?
8-MG-BA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfMeG1KSzVyPUWuPVMhdk1? M2[2XnNCVkeHUh?=
SK-HEP-1 NY\XVY5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7qTWM2OD14LkG0JI5O M4\PcnNCVkeHUh?=
697 M1jDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTZwMkWgcm0> NWrubYNoW0GQR1XS
KYSE-450 NGLRc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTGV3lKSzVyPU[uN|Ihdk1? MlnDV2FPT0WU
HCC2998 M3TsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXjdG06UUN3ME22MlM1KG6P Ml\yV2FPT0WU
HD-MY-Z MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3CTHlKSzVyPU[uOlghdk1? M3\nPHNCVkeHUh?=
OS-RC-2 NX7KPXpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomwTWM2OD14Lk[4JI5O NUnTXm5HW0GQR1XS
SF126 M{n5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrXTWM2OD15LkC1JI5O Mmq2V2FPT0WU
Ca-Ski NG\IO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fjcmlEPTB;Nz6wPUBvVQ>? M1[1PHNCVkeHUh?=
NCI-H358 NV\5N3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmftTWM2OD15LkG2JI5O NXHLfZlXW0GQR1XS
J82 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPEdYtKSzVyPUeuOFEhdk1? NF3PNWFUSU6JRWK=
NCI-H2342 NX;rdlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjOTWM2OD15Lk[zJI5O MXvTRW5ITVJ?
OVCAR-8 NFv0ZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLHTWM2OD15Lkmgcm0> Mn\sV2FPT0WU
TE-8 NIDQeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHvTWM2OD16IH7N NUHTc|hPW0GQR1XS
ETK-1 NVXLboZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTtNJF{UUN3ME24MlA5KG6P NV32b|Q4W0GQR1XS
HAL-01 M3\r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRThwMjDuUS=> NH\0cHFUSU6JRWK=
KYSE-150 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRThwNEegcm0> NVLGTlhjW0GQR1XS
NCI-H810 NUHqNXQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRThwNU[gcm0> NGPZeHhUSU6JRWK=
ONS-76 NHPoUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHmd21XUUN3ME24MlY5KG6P NWLx[Vg1W0GQR1XS
NMC-G1 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fmfWlEPTB;OD63OkBvVQ>? NHi3NoNUSU6JRWK=
C3A NVLwZVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HjS2lEPTB;OD64OEBvVQ>? MnHxV2FPT0WU
PA-1 NIKxUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nNUmlEPTB;OD65PUBvVQ>? NVW2RXVQW0GQR1XS
SH-4 MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXJTWM2OD17LkCyJI5O MkHwV2FPT0WU
EFO-27 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHqdZZKSzVyPUmuNFUhdk1? Mor5V2FPT0WU
CAPAN-1 M2rSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jMXGlEPTB;OT6yN{BvVQ>? NF3OTmhUSU6JRWK=
DU-145 M3fHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLRcYxKSzVyPUmuNlkhdk1? MkHIV2FPT0WU
A101D MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HNRmlEPTB;OT6zO{BvVQ>? NFftNVZUSU6JRWK=
ST486 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTlwNEGgcm0> NIm3NoxUSU6JRWK=
NCI-H1437 NHTVO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrYTWM2OD17LkSyJI5O M{fGTnNCVkeHUh?=
HGC-27 M{TGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLGWJFKSzVyPUmuOkBvVQ>? MYPTRW5ITVJ?
8305C MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXTbo4zUUN3ME25MlY1KG6P Mlz0V2FPT0WU
OCUB-M MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFyLkCzJI5O MXXTRW5ITVJ?
COLO-679 M2LQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFyLkC3JI5O NI\XZVZUSU6JRWK=
Detroit562 NUS2O4pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i0PWlEPTB;MUCuOFIhdk1? NUexNFV3W0GQR1XS
A204 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWwTWM2OD1zMT6xOkBvVQ>? MWDTRW5ITVJ?
NCI-H1734 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfZUZJKSzVyPUGxMlI6KG6P MV3TRW5ITVJ?
MC-CAR MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTFNnFvUUN3ME2xNU42QCCwTR?= NVLsR5JJW0GQR1XS
NCI-H2170 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Nc4RPUUN3ME2xNU46PyCwTR?= MYPTRW5ITVJ?
NCI-SNU-5 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzwTWM2OD1zMj6xN{BvVQ>? MkmwV2FPT0WU
HCE-T NXvJfGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnUTWM2OD1zMj60NkBvVQ>? MkDnV2FPT0WU
KYSE-180 NHzqV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorkTWM2OD1zMj64NUBvVQ>? M1LrcHNCVkeHUh?=
C8166 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF|LkC4JI5O M3jQPHNCVkeHUh?=
NCI-H460 NHHFRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF|LkW0JI5O NXfvWJRyW0GQR1XS
SNU-449 M1T0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTP[GE5UUN3ME2xN{44PyCwTR?= NWrJ[YNZW0GQR1XS
MDA-MB-468 NETWc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnw[YdYUUN3ME2xOE4yOiCwTR?= MXrTRW5ITVJ?
COR-L23 NYXoXVlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF2LkGzJI5O MnHNV2FPT0WU
CTV-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofZTWM2OD1zND6xOEBvVQ>? M1LsR3NCVkeHUh?=
BL-41 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjhVG9sUUN3ME2xOE4{PyCwTR?= MWDTRW5ITVJ?
IGR-1 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGye2t4UUN3ME2xOE41OiCwTR?= NG\xR|lUSU6JRWK=
TK10 M3rXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn0cnREUUN3ME2xOE41QSCwTR?= MlH4V2FPT0WU
REH MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH2dGxDUUN3ME2xOE42OSCwTR?= NXTnOGVPW0GQR1XS
LU-139 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrXTWM2OD1zND61PUBvVQ>? NYnGTlZIW0GQR1XS
KP-N-YS NELmb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz2WWlKSzVyPUG0Mlk4KG6P M4W5ZXNCVkeHUh?=
PANC-10-05 NW\0b3RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzVU2xNUUN3ME2xOU4{QCCwTR?= NWfaRlB7W0GQR1XS
HL-60 M1rvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPLTWM2OD1zNT62PUBvVQ>? MnzOV2FPT0WU
T84 NYntO|hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF3Lkm2JI5O M{PNWXNCVkeHUh?=
RPMI-8226 MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF4LkCyJI5O MYPTRW5ITVJ?
UM-UC-3 NInZXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL6THZKSzVyPUG2MlE3KG6P MUHTRW5ITVJ?
TE-10 NUCxem1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;rdmlEPTB;MU[uNlEhdk1? MYDTRW5ITVJ?
CAL-148 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTyO5FKSzVyPUG3MlI{KG6P M32zZXNCVkeHUh?=
BV-173 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2myRmlEPTB;MUeuNlchdk1? Mlu1V2FPT0WU
Calu-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF5LkK5JI5O NYPyWYc6W0GQR1XS
RPMI-2650 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLvPYczUUN3ME2xO{42QSCwTR?= MlvJV2FPT0WU
MKN45 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\yeHQ{UUN3ME2xO{44OyCwTR?= MY\TRW5ITVJ?
NUGC-3 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfETWM2OD1zOD6zOEBvVQ>? MmXhV2FPT0WU
NCI-H520 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnThTWM2OD1zOD63O{BvVQ>? M2TPNHNCVkeHUh?=
CCRF-CEM NWXmXXM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[2RlNKSzVyPUG4Mlg2KG6P NI\MRldUSU6JRWK=
NCI-H2405 NI\hcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXEdZQ2UUN3ME2xPU4yKG6P M3naUXNCVkeHUh?=
ES7 M2jQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDnUFkzUUN3ME2xPU44PiCwTR?= MYXTRW5ITVJ?
BPH-1 NWLofllwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP5O4tkUUN3ME2yNE4zQCCwTR?= M4DQV3NCVkeHUh?=
SAS NVPUR5VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XDcWlEPTB;MkCuOUBvVQ>? NHjte|lUSU6JRWK=
HuCCT1 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fzOGlEPTB;MkCuOVghdk1? MkfZV2FPT0WU
LOUCY NEH0fFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[1eGlEPTB;MkCuOlYhdk1? MV3TRW5ITVJ?
NCI-H292 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJyLke5JI5O NYDnNXpqW0GQR1XS
G-361 NUnPbpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrGNHdKSzVyPUKxMlA4KG6P NIDxUXJUSU6JRWK=
M059J MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInGVZRKSzVyPUKxMlA5KG6P NU[3VmRCW0GQR1XS
NCI-H1651 NV7Sb5h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rxOWlEPTB;MkGuNVEhdk1? NEX0PINUSU6JRWK=
KALS-1 M1;HbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DhZWlEPTB;MkGuN|khdk1? NYLBXJZSW0GQR1XS
DJM-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXVSItKSzVyPUKxMlU6KG6P NY\KWFBJW0GQR1XS
AU565 NIDnb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3QU4RKSzVyPUKxMlg{KG6P MYfTRW5ITVJ?
HCC38 M33vUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXENYRKSzVyPUKxMlk2KG6P NVv0U4ZqW0GQR1XS
U251 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\vTWM2OD1{Mj6yO{BvVQ>? NEHNUoxUSU6JRWK=
ABC-1 NI\DXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG1U3pKSzVyPUKyMlY2KG6P NXni[|NEW0GQR1XS
SK-NEP-1 NWHqT4ttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTYSnhKSzVyPUKyMlk{KG6P M4L6TnNCVkeHUh?=
CESS NX:y[GxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DDS2lEPTB;MkOuNVkhdk1? NGXaVndUSU6JRWK=
MIA-PaCa-2 NW[0T4M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i4c2lEPTB;MkOuN|Yhdk1? M{fzPHNCVkeHUh?=
SUP-T1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXZN3lEUUN3ME2yN{41PyCwTR?= MkfIV2FPT0WU
L-428 M1PLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDpUYFKSzVyPUKzMlYzKG6P MYPTRW5ITVJ?
SW954 M4W2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHXV2hKUUN3ME2yN{43QCCwTR?= MkDTV2FPT0WU
HO-1-N-1 NH;oRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HVdmlEPTB;MkOuO|chdk1? MXHTRW5ITVJ?
CHP-126 NHLmcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILGW|FKSzVyPUK0MlE1KG6P NIPkZ49USU6JRWK=
HMV-II NHXHeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ2LkO0JI5O M2K3UXNCVkeHUh?=
NB10 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK4TWM2OD1{ND6zO{BvVQ>? NGrNNZVUSU6JRWK=
A172 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLOPZVKSzVyPUK0MlcyKG6P NFzXbJBUSU6JRWK=
MONO-MAC-6 M3\IZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ixTGlEPTB;MkSuPFQhdk1? NXjFbFJYW0GQR1XS
NCI-H1650 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfCTWM2OD1{NT60JI5O M4nJVHNCVkeHUh?=
NH-12 NXPDfI5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;HTWM2OD1{NT61JI5O MnjXV2FPT0WU
ML-2 NF\1NIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPMfVZKSzVyPUK1Mlc1KG6P NGHLZ4ZUSU6JRWK=
MZ2-MEL Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ4LkKyJI5O NEfXeZdUSU6JRWK=
COLO-684 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ4LkSxJI5O M1TmO3NCVkeHUh?=
HuP-T4 NHzy[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTmTWM2OD1{Nz6zJI5O MXzTRW5ITVJ?
SW837 NFTWRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjlVlJ3UUN3ME2yO{43OiCwTR?= M1SzXXNCVkeHUh?=
MDA-MB-231 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSx[nJkUUN3ME2yO{44QCCwTR?= NIjCVW9USU6JRWK=
KYSE-140 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrUTFVyUUN3ME2yO{46OSCwTR?= MkGwV2FPT0WU
NOMO-1 M2DaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXHNVlKSzVyPUK4MlY5KG6P MXLTRW5ITVJ?
GP5d MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PrNWlEPTB;MkiuO|Ihdk1? NFnHVmlUSU6JRWK=
COR-L105 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJ7LkSyJI5O M1Hqd3NCVkeHUh?=
LS-411N NFjCVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ7Lki4JI5O NULmWI52W0GQR1XS
NY MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNyLkG4JI5O MnzKV2FPT0WU
NCI-H2030 NX;pblZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n0XWlEPTB;M{CuOFUhdk1? NWnTW3VRW0GQR1XS
CCF-STTG1 NG\YWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;4TWM2OD1|MT60NkBvVQ>? NGPOVmFUSU6JRWK=
NCI-H1703 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvhdJVKSzVyPUOxMlc5KG6P NIHodZpUSU6JRWK=
TUR NXzKWnZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLWfnZKSzVyPUOyMlA{KG6P M1vaU3NCVkeHUh?=
NOS-1 NH\6dm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2joS2lEPTB;M{KuOFQhdk1? M1PPdXNCVkeHUh?=
A2058 NFjDOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;MSllLUUN3ME2zNk45OyCwTR?= NXi4UnN{W0GQR1XS
LCLC-103H MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH1bVZ1UUN3ME2zN{4zPSCwTR?= M3L4XXNCVkeHUh?=
NCI-H510A NUPOZ5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX6TWM2OD1|Mz6yO{BvVQ>? NVLMVYg3W0GQR1XS
BC-1 M{fOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC4TWM2OD1|Mz63O{BvVQ>? NUfRZVJ4W0GQR1XS
SK-CO-1 NWezS3ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn25TWM2OD1|ND6wNUBvVQ>? MoHoV2FPT0WU
A673 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN2LkG3JI5O MX7TRW5ITVJ?
VM-CUB-1 M2LHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fCd2lEPTB;M{SuOlkhdk1? MmnqV2FPT0WU
HH MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPJTWM2OD1|NT6wOkBvVQ>? NFzCdnVUSU6JRWK=
CAL-27 NEjHZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;DbGlEPTB;M{WuNVYhdk1? M1XXeXNCVkeHUh?=
NEC8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jFWWlEPTB;M{WuN|chdk1? MVHTRW5ITVJ?
BxPC-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLyTFV3UUN3ME2zOk46OSCwTR?= M3u4[HNCVkeHUh?=
SNB75 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvi[FRKSzVyPUO3MlI1KG6P M{\r[3NCVkeHUh?=
NB13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDtWnlKSzVyPUO4MlI{KG6P MXPTRW5ITVJ?
SK-OV-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HEdmlEPTB;M{iuO|Qhdk1? MnvyV2FPT0WU
ME-180 NVjLWnI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDTTWM2OD1|OD64JI5O MlzUV2FPT0WU
JiyoyeP-2003 NEeyfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHqTWM2OD1|OT6zPEBvVQ>? NH7Od3pUSU6JRWK=
LU-134-A MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjq[I5YUUN3ME20NE4xOiCwTR?= NYnOcFlmW0GQR1XS
LS-123 NVyzPVZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRyLkK4JI5O M4\nT3NCVkeHUh?=
COLO-800 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\hT|R3UUN3ME20NE42PiCwTR?= MlzyV2FPT0WU
LB831-BLC NID0ZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO1O5pKSzVyPUSxMlg2KG6P MnjFV2FPT0WU
NCI-H747 M1jUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYruSGpHUUN3ME20Nk4zQCCwTR?= MmLUV2FPT0WU
MZ7-mel NWHxU2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK0TWM2OD12Mj62OkBvVQ>? M17EenNCVkeHUh?=
GT3TKB M2njVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILneWVKSzVyPUSyMlczKG6P M3GxdXNCVkeHUh?=
MOLT-16 NF\TUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzvSYRKSzVyPUSzMlA2KG6P M{jSbnNCVkeHUh?=
23132-87 NYP2OYlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HuZWlEPTB;NEOuNFUhdk1? MkjSV2FPT0WU
PF-382 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzvTWM2OD12ND6yNkBvVQ>? NGHuc4hUSU6JRWK=
ES3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPxTWM2OD12ND62JI5O NEK2RVRUSU6JRWK=
SW756 NU\BRmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvNb2pwUUN3ME20OU4yPCCwTR?= NEX0SopUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water (warmed)
混合させたのち直ちに使用することを推奨します。
52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
保管
in solvent
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID